Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

14 of 14+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · P01

  Understanding and targeting treatment-associated lineage plasticity in cancer

  Columbia University Health Sciences· New York, United States· US$2,729,322 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  The role of GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer and immune evasion

  Methodist Hospital Research Institute· Houston, United States· US$514,864 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Elucidating upstream and downstream NUAK2 mechanisms in neuroendocrine prostate cancer

  Augusta University· Augusta, United States· US$518,589 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R56

  The role of AKT isoform-preferred substrates in prostate cancer aggressiveness

  Roswell Park Cancer Institute Corp· Buffalo, United States· US$130,125 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  Analysis of epithelial heterogeneity and plasticity in prostate development and cancer

  Columbia University Health Sciences· New York, United States· US$613,866 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

10 of 74 running projects, newest first. Listed amounts together: US$30.6m + €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Updated 6 Nov 2025

  “The Sponsor has achieved its objectives.”Registry text, quoted unchanged. Source

• Terminated

  Genetic Testing for Men With Metastatic Prostate Cancer

  NCT03503097· University of Washington· Updated 1 Oct 2025

  “Study closed to accrual before meeting enrollment goal due to end of funding.”Registry text, quoted unchanged. Source

• Terminated

  Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

  NCT04182516· Nerviano Medical Sciences· Updated 19 Sept 2024

  “The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Updated 2 May 2024

  “No subjects enrolled in the study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer

  NCT00261456· Institute of Cancer Research, United Kingdom· Source

• Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations

  NCT02705846· Institute of Cancer Research, United Kingdom· Source

• Study of How People Make Decisions About Prostate Cancer Risk

  NCT07197723· Memorial Sloan Kettering Cancer Center· Source

• Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

  NCT05457257· AstraZeneca· Source

• A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

  NCT06614751· Danatlas Pharmaceuticals Co., Ltd· Source

• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Cancer morbidity and mortality in individuals with obsessive-compulsive disorder: a population-based and sibling cohort study in Sweden and Denmark.

  BMC Med, Nov 2026

• Comparative functional and oncologic outcomes of radical prostatectomy using the da Vinci Xi versus da Vinci 5: an inverse probability-weighted analysis.

  World J Urol, Nov 2026

• Sleep duration and prostate cancer-specific mortality in the Southern Community Cohort Study.

  Cancer Causes Control, Oct 2026

• Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care.

  Support Care Cancer, Oct 2026

• Pathological fracture as initial manifestation of malignancy and survival based on diagnoses: a register-based cohort study from the Swedish Fracture Register and the Swedish Cancer Register.

  Acta Orthop, Oct 2026

• Oncological outcomes after Senhance robot-assisted radical prostatectomy: biochemical recurrence and risk stratification in a large single-centre cohort.

  J Robot Surg, Oct 2026

• Association of Travel Time With Definitive Prostate Cancer Treatment: A United States Registry Cohort Study.

  Cancer Med, Oct 2026

• Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer.

  JAMA Netw Open, Oct 2026

• Leveraging Artificial Intelligence to Monitor Patients With Prostate Cancer in a Retrospective Cohort of Radiation Oncology Clinic Patients.

  Clin J Oncol Nurs, Sept 2026

• TAPESTRY study: impact of prior transurethral resection of the prostate on outcomes after robot-assisted radical prostatectomy: a propensity score-matched cohort study.

  J Robot Surg, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.